Form 8-K - Current report:
SEC Accession No. 0001401914-22-000024
Filing Date
2022-03-31
Accepted
2022-03-31 08:05:27
Documents
20
Period of Report
2022-03-31
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K dare-20220331.htm   iXBRL 8-K 36223
2 EX-99.1 ex991_earningspr033122.htm EX-99.1 22135
6 ex991_earningspr033122001.jpg GRAPHIC 184684
7 ex991_earningspr033122002.jpg GRAPHIC 222823
8 ex991_earningspr033122003.jpg GRAPHIC 203103
9 ex991_earningspr033122004.jpg GRAPHIC 254840
10 ex991_earningspr033122005.jpg GRAPHIC 320118
11 ex991_earningspr033122006.jpg GRAPHIC 235040
12 ex991_earningspr033122007.jpg GRAPHIC 131317
  Complete submission text file 0001401914-22-000024.txt   2341652

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT dare-20220331.xsd EX-101.SCH 1921
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT dare-20220331_lab.xml EX-101.LAB 23892
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT dare-20220331_pre.xml EX-101.PRE 12539
14 EXTRACTED XBRL INSTANCE DOCUMENT dare-20220331_htm.xml XML 10745
Mailing Address 3655 NOBEL DRIVE SUITE 260 SAN DIEGO CA 92122
Business Address 3655 NOBEL DRIVE SUITE 260 SAN DIEGO CA 92122 858-926-7655
Dare Bioscience, Inc. (Filer) CIK: 0001401914 (see all company filings)

EIN.: 204139823 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36395 | Film No.: 22789207
SIC: 2834 Pharmaceutical Preparations